Dual specificity mitogen-activated protein kinase kinase; MEK1/2 · PROTEIN FAMILY · Homo sapiens
This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.
Move to another high-traffic target or paste a specific ChEMBL target ID.
Structured disease, protein, and project context should read before the lower-level identity rail.
As of 2026-09-14Dual specificity mitogen-activated protein kinase kinase; MEK1/2 shows approved-linked disease relevance led by cancer. 5 more disease programs remain visible in the same review block. 1 linked drug keeps the current disease frame grounded. Protein identity stays anchored to UniProt P36507. Start with cancer, then reuse UniProt P36507 as the stable protein anchor across project notes and exports.
Start with cancer, then reuse UniProt P36507 as the stable protein anchor across project notes and exports.
Dual specificity mitogen-activated protein kinase kinase; MEK1/2 shows approved-linked disease relevance led by cancer. 5 more disease programs remain visible in the same review block. 1 linked drug remains visible in the same block.
Start review with cancer because it currently carries approved-linked support. Linked drugs include TRAMETINIB. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
Disease source · ChEMBL drug mechanism + indication proxyDual specificity mitogen-activated protein kinase kinase 2
Review this target as Dual specificity mitogen-activated protein kinase kinase; MEK1/2, mapped to UniProt P36507. ChEMBL maps the protein component as Dual specificity mitogen-activated protein kinase kinase 2. Sequence length is 400 aa.
Protein source · UniProt accession via ChEMBL component mappingKeep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.
This review treats Dual specificity mitogen-activated protein kinase kinase; MEK1/2 as ChEMBL target CHEMBL2111289, mapped to UniProt P36507. Disease framing currently uses the Open Targets-ready proxy contract.
Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.
Choose the first block or source based on the question you are trying to answer.
Start here when your first question is whether Dual specificity mitogen-activated protein kinase kinase; MEK1/2 is the right protein anchor across sources, using UniProt P36507 as the stable mapping.
Jump to Protein ContextUse this block first when you need to confirm why cancer is currently framed as approved-linked support. It currently carries 1 linked drug in the same disease frame.
Jump to Disease ContextOpen the one-page evidence card when you want the rationale, activity base, and attribution together.
Open Review-ready CardVerify identity, organism, and the fastest next research jumps from the same page.
| Preferred Name | Dual specificity mitogen-activated protein kinase kinase; MEK1/2 |
| Target Type | PROTEIN FAMILY |
| Organism | Homo sapiens |
| UniProt | P36507 |
Reviewable protein naming and mapping context for this target snapshot.
| Protein Label | Dual specificity mitogen-activated protein kinase kinase 2 |
| UniProt Accession | P36507 |
| Component Type | Protein |
| Sequence Length | 400 aa |
Dual specificity mitogen-activated protein kinase kinase 2
Review this target as Dual specificity mitogen-activated protein kinase kinase; MEK1/2, mapped to UniProt P36507. ChEMBL maps the protein component as Dual specificity mitogen-activated protein kinase kinase 2. Sequence length is 400 aa.
Open Targets-ready disease context using the current target-indication evidence contract.
Dual specificity mitogen-activated protein kinase kinase; MEK1/2 shows approved-linked disease relevance led by cancer. 5 more disease programs remain visible in the same review block.
Start review with cancer because it currently carries approved-linked support. Linked drugs include TRAMETINIB. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
| ChEMBL ID | pChEMBL | Type | Value (nM) | Phase |
|---|---|---|---|---|
| CHEMBL2146883 | 9.7 | IC50 | 0.2 | Approved |
| CHEMBL450775 | 9.05 | IC50 | 0.9 | Preclinical |
| CHEMBL244488 | 8.92 | IC50 | 1.2 | Preclinical |
| CHEMBL3182051 | 8.85 | IC50 | 1.4 | Preclinical |
| CHEMBL2103875 | 8.7 | IC50 | 2.0 | Approved |
| CHEMBL2146893 | 8.43 | IC50 | 3.7 | Preclinical |
| CHEMBL442235 | 8.4 | IC50 | 4.0 | Preclinical |
| CHEMBL234887 | 8.3 | IC50 | 5.0 | Preclinical |
| CHEMBL1933935 | 8.22 | IC50 | 6.0 | Preclinical |
| CHEMBL2146892 | 8.16 | IC50 | 6.9 | Preclinical |
| BAO Format | Assays | Compounds | Avg pChEMBL |
|---|---|---|---|
| cell-based format | 103 | 21 | 7.2 |
| protein format | 21 | 15 | 7.2 |
| assay format | 15 | 27 | 6.8 |
| subcellular format | 8 | 0 | — |
| tissue-based format | 1 | 0 | — |
| BAO Format | Assays | Compounds | Avg pChEMBL |
|---|---|---|---|
| assay format | 9 | 47 | 6.2 |
| organism-based format | 9 | 0 | — |
| cell-based format | 2 | 0 | — |
| BAO Format | Assays | Compounds | Avg pChEMBL |
|---|---|---|---|
| cell-based format | 1 | 0 | — |